AtaiBeckley (ATAI) Depreciation & Amortization (CF) (2020 - 2026)
AtaiBeckley (ATAI) reported Depreciation & Amortization (CF) of $233000.0 for Q3 2025, up 180.72% on a YoY basis from $83000.0 in Q3 2024, and up 2.64% sequentially from $227000.0 in Q2 2025.
AtaiBeckley (ATAI) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
AtaiBeckley's Depreciation & Amortization (CF) history runs 2 years deep, the most recent figure standing at $167000.0 for Q1 2026.
- On a quarterly basis, Depreciation & Amortization (CF) fell 22.69% year-over-year to $167000.0 in Q1 2026; TTM through Mar 2026 was $383000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $1.0 million, up 113.95% from the prior year.
- Depreciation & Amortization (CF) climbed to $233000.0 in Q3 2025, from $227000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $216000.0 in Q1 2025 and bottomed at $167000.0 in Q1 2026.
- A 5-year average of $88578.9 and a median of $74000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- Across the five-year window, Depreciation & Amortization (CF) slumped 240.0% in 2021 and surged 900.0% in 2022, its largest moves.
- Tracing ATAI's Depreciation & Amortization (CF) over 5 years: stood at $29000.0 in 2021, then surged by 82.76% to $53000.0 in 2022, then surged by 90.57% to $101000.0 in 2023, then jumped by 122.77% to $225000.0 in 2024, then gained by 3.56% to $233000.0 in 2025.
- Business Quant data shows ATAI's Depreciation & Amortization (CF) at $233000.0 in Q3 2025, $227000.0 in Q2 2025, and $216000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | AtaiBeckley | 2.56 Bn | 2.56 Bn | - | 233,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 167,000.00 |
| Mar 31, 2026 | 167,000.00 |
| Sep 30, 2025 | 233,000.00 |
| Sep 30, 2025 | 233,000.00 |
| Jun 30, 2025 | 227,000.00 |
| Jun 30, 2025 | 227,000.00 |
| Mar 31, 2025 | 216,000.00 |
| Mar 31, 2025 | 216,000.00 |
| Mar 31, 2025 | 216,000.00 |
| Mar 31, 2025 | 216,000.00 |
| Dec 31, 2024 | 225,000.00 |
| Dec 31, 2024 | 225,000.00 |
| Sep 30, 2024 | 83,000.00 |
| Sep 30, 2024 | 83,000.00 |
| Jun 30, 2024 | 82,000.00 |
| Jun 30, 2024 | 82,000.00 |
| Mar 31, 2024 | 83,000.00 |
| Mar 31, 2024 | 83,000.00 |
| Dec 31, 2023 | 101,000.00 |
| Dec 31, 2023 | 101,000.00 |